All News

Oral ensitrelvir given within 72 hours cuts household symptomatic COVID-19 by 67%, showing safe postexposure prevention.

As diabetes rises to be one of the most prominent chronic diseases globally, pharmacists have reached out as key resources for preventing and managing its complications.

Meta-analysis shows empagliflozin is superior to sitagliptin with metformin for glycemic control.

HHS targets SSRI overuse, urging pharmacists and clinicians to reassess long-term therapy, use safer tapers, and expand nondrug care.

As health officials respond to ongoing concerns, Nathan Ott, PharmD, joined to discuss key hantavirus facts that pharmacists can relay to their communities.

Among both childhood and adult populations, researchers assess the quality of life across a large cohort of patients reporting pneumococcal disease cases.

Mapping data reveals where pharmacy access collapses and how policymakers can fight medication deserts.

The FDA seeks to bar bulk compounding of semaglutide, tirzepatide, and liraglutide, spotlighting risks in online glucagon-like peptide-1 copies.

In part 2, Staci-Marie Norman, PharmD, CDCES, FAPhA, and Susan Cornell, PharmD, CDCES, FAPhA, FADCES, discuss the pharmacist’s ability to meander a booming medication class in GLP-1s.

Pharmacists expand into vaccines and telehealth, but state laws and reimbursement gaps persist.

Despite common trends in the specialty drug market persisting, a new pharmacy landscape must come together to address rising issues.

Preventing pneumococcal disease remains a cornerstone of public health, yet the strategy for protection is increasingly individualized and complex.

ECO 2026 data shows Wegovy cuts migraines, depression, and heart risk in menopausal women, as glucagon-like peptide-1s' demand challenges pharmacists.

Beyond medications, lifestyle modifications can also help patients curb allergy symptoms.

Opioid pain care shifts fast, and pharmacists and pharmacies lead safer prescribing, naloxone education, and monitoring to curb overdose deaths.

This episode explores the differences between behavior that is caught rather than taught, explaining how leadership can be a learned skill if properly approached.

Susan Cornell, PharmD, CDCES, FAPhA, FADCES, and Staci-Marie Norman, PharmD, CDCES, FAPhA, discuss current trends regarding CGM use and access behind the pharmacy counter.

Researchers explore invasive pneumococcal disease epidemiology after the introduction of multiple pneumococcal conjugate vaccines.

New research shows inflammation and diabetes raise preterm birth risk, suggesting C-reactive protein testing.

The weight-loss and diabetes drug will now be available via Amazon Pharmacy for same-day delivery or in-person kiosk pickup.

Medicare’s new GLP‑1 bridge program launches soon, easing access without shortages, and pharamcists are at the focal point of these transitions.

As artificial intelligence becomes commonplace in medical practice, officials are gradually uncovering significant safety risks.

By late February 2026, national data from the CDC reveal a test positivity rate of 9.1%, the highest recorded for the entire season at that point.

With value-based care initiatives on the rise in the US health care system, one partnership in Ohio is showing early signs of significant success.

CMS pilots BALANCE and GLP-1 Bridge models to widen Medicare/Medicaid obesity drug coverage, spotlighting pharmacists’ role in access and safe therapy.

Exploring data across a variety of income settings, researchers conduct a review of invasive pneumococcal disease carriage, cases, and their associations.

A PQA program shows how value-based pharmacy contracts, shared metrics, and better data boost immunizations and patient outcomes beyond dispensing.

Episode 10 explores recent guideline changes in clinicians’ management of dyslipidemia, highlighting much more than a few updated recommendations.